RHO and ovarian carcinoma: RAC1 and other members of the Rho family of GTPases have been implicated as key modulators of sensitivity to DNA-damaging agents; in particular, chemical inhibition of RAC1 has been shown to sensitize drug-resistant ovarian cancer cell lines to cisplatin [51–53].